BridgeMD
New treatment option for Radiation-induced Dermatitis
Official title Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
ClinicalTrials.gov ID: NCT07353671
What this study is testing
What is Topical application of Periplaneta americana-derived Meilian Fuxin Solution?
Topical application of Periplaneta americana-derived Meilian Fuxin Solution is an investigational medicine, given as an once-daily treatment applied to the skin, being studied as a potential treatment for radiation-induced dermatitis.
Also referred to as MLFX, Periplaneta Americana Extract.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.
- Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and...
- Performance Status: Patients with an ECOG Performance Status score of 0 to 2.
- Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form.
You likely can't join if
- Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area.
- Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with how well it works assessment (e.g., presence of open...
- Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses.
- Known Allergies: Known allergy to any component of the investigational product (Meilian Fuxin Solution).
- Prior Clinical Research: Participation in other treatment clinical studies within the past 3 months and use of any investigational drugs or devices.
- Investigator Discretion: people judged by the investigator to be unsuitable for participation in this clinical study.
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.